CD40LG and central nervous system neoplasm: Direct administration of recombinant CD40L was pursued in non-CNS tumors with a promising safety profile [179] and is being tested as a fusion protein with SIRPα to initiate checkpoint blockade (ClinicalTrials.gov Identifier: NCT04406623).